Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study

Lancet Oncology

Volumn 8, Issue 5, 2007, Pages 395-402

  Tagalakis, Vicky ^a   Tamim, Hani ^b   Blostein, Mark ^a   Collet, Jean Paul ^c   Hanley, James A ^d   Kahn, Susan R ^a  

^a MCGILL UNIVERSITY   (Canada)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Departments of Epidemiology Biostatistics and Occupational Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN; ANTIANDROGEN; ANTICOAGULANT AGENT; ANTIESTROGEN; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ADULT; AGE; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANADA; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; KIDNEY CANCER; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; SEX DIFFERENCE; TREATMENT DURATION; UROGENITAL TRACT CANCER; UTERUS CANCER; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SASKATCHEWAN; UROGENITAL NEOPLASMS; WARFARIN;

EID: 34247182177     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70046-3     Document Type: Article

References (33)

1. Zacharski L., Henderson W., Rickles F., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53 (1984) 2046-2052
2. Schulman S., Rhedin A., Lindmarker P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 342 (2000) 1330-1338
3. Taliani M., Agnelli G., Prandoni P., et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 1 (2003) 1730-1733
4. Downey W., Beck P., McNutt M., Stang M., Osei W., and Nichol J. Health databases in Saskatchewan. In: Strom B. (Ed). Pharmacoepidemiology. 3rd edn. (2000), Wiley, Chichester 325-345
5. In: Fritz A., Percy C., Jack A., et al. (Eds). International Classification of Diseases for Oncology. 3rd edn. (2000), World Health Organization, Geneva, Switzerland
6. Socioeconomic Data and Applications Center's (SEDAC). Stratopheric ozone and human health project. Saskatchewan Cancer Registry. http://sedac.ciesin.columbia.edu/ozone/regs/saskatchewan.html (accessed Jan 18, 2007).
7. Rawson N., and Robson D. Concordance on the recording of cancer in the Saskatchewan Cancer Agency Registry, hospital charts and death registrations. Can J Public Health 91 (2000) 390-393
8. Ronquist G., Rodriguez L., Ruigomez A., et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 58 (2004) 50-56
9. Perron L., Bairati I., Harel F., and Meyer F. Antihypertensive drug use and the risk of prostate cancer. Cancer Causes Control 15 (2004) 535-541
10. Skarsgard D., and Tonita J. Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control 11 (2000) 79-88
11. Statistics Canada-Government of Canada. Number of migrants and net migration rates by age group for Saskatchewan, 1996-2001. http://www12.statcan.ca/english/census01/products/analytic/companion/mob/tables/high/mig_ageSK.cfm (accessed Dec 12, 2006).
12. Blumentals W., Foulis P., Schwartz S., and Mason T. Does warfarin therapy influence the risk of bladder cancer?. J Thromb Haemost 91 (2004) 801-805
13. In: Ries L., Eisner M., Kosary C., et al. (Eds). SEER Cancer Statistics Review (1973-1999), National Cancer Institute, Bethesda, MD, USA. http://seer.cancer.gov/publications/ethnicity/prostate.pdf (accessed March 23, 2007).
14. Chan J., Gann P., and Giovannucci E. Role of diet in prostate cancer development and progression. J Clin Oncol 10 (2005) 8152-8160
15. Plaskon L., Penson D., Vaughan T., and Stanford J. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 12 (2003) 604-609
16. Lindblad P., Chow W., Chan J., et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42 (1999) 107-112
17. Inoue M., Iwasaki M., Otani T., et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166 (2006) 1871-1877
18. Larsson S., Orsini N., Brismar K., and Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49 (2006) 2819-2823
19. Kasper J., and Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 2056-2062
20. Mahmud S., Franco E., and Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90 (2004) 93-99
21. Klerk C., Smorenburg S., Otten H., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 (2005) 2130-2135
22. Kakkar A., Levine M., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 15 (2004) 1944-1948
23. Shannon J., Tewoderos S., Garzotto M., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162 (2005) 318-325
24. Singal R., Khurana V., Caldito G., and Fort C. Statins and prostate cancer risk: a large case-control study in veterans. J Clin Oncol 23 suppl (2005) 16S 1004 (abstr).
25. Bonovas S., Filioussi K., Tsavaris N., and Sitaras N. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24 (2006) 4808-4817
26. Hebert P., Gaziano J., Chan K., and Hennekens C. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278 (1997) 313-321
27. Bjerre L., and LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110 (2001) 716-723
28. Dale K., Coleman C., Henyan N., Kluger J., and White C. Statins and cancer risk: A meta-analysis. JAMA 295 (2006) 74-80
29. Baigent C., Keech A., Kearney P., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
30. Sorensen H., Mellemkjaer L., Steffensen F., Olsen J., and Nielsen G. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338 (1998) 1169-1173
31. Omabarsha B., Fair W., and Heston W. Effect of coumarin on normal rat prostate and R-3327H prostatic adenocarcinoma. Cancer Res 49 (1989) 3045-3049
32. Wu Y., Robinson D., and Kung H. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 64 (2004) 7311-7320
33. Sainaghi P., Costello L., Bergamasco L., Galletti M., Bellosta P., and Avanzi G. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204 (2005) 36-44